Cargando…

Aggressiveness of care at end of life in patients with high‐grade glioma

BACKGROUND: Patients with high‐grade glioma (HGG) face unique challenges toward the end of life (EoL), given their aggressive trajectory and neurologic deterioration. Aggressiveness of medical care at EoL has been identified as an important quality metric for oncology patients. At this time, limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Rebecca A., Ou, Alexander, Naqvi, Syed M. A. A., Naqvi, Syed M., Weathers, Shiao‐Pei S., O'Brien, Barbara J., de Groot, John F., Bruera, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633215/
https://www.ncbi.nlm.nih.gov/pubmed/34755486
http://dx.doi.org/10.1002/cam4.4344
_version_ 1784607882888609792
author Harrison, Rebecca A.
Ou, Alexander
Naqvi, Syed M. A. A.
Naqvi, Syed M.
Weathers, Shiao‐Pei S.
O'Brien, Barbara J.
de Groot, John F.
Bruera, Eduardo
author_facet Harrison, Rebecca A.
Ou, Alexander
Naqvi, Syed M. A. A.
Naqvi, Syed M.
Weathers, Shiao‐Pei S.
O'Brien, Barbara J.
de Groot, John F.
Bruera, Eduardo
author_sort Harrison, Rebecca A.
collection PubMed
description BACKGROUND: Patients with high‐grade glioma (HGG) face unique challenges toward the end of life (EoL), given their aggressive trajectory and neurologic deterioration. Aggressiveness of medical care at EoL has been identified as an important quality metric for oncology patients. At this time, limited data exist around the nature of EoL care of patients with HGG. METHODS: Patients with HGG and palliative care (PC) referral seen between 2010 and 2015 were identified (N = 80). Of these, N = 52 met inclusion criteria. Random selections of patients with (1) HGG not referred to PC (n = 80), and (2) non‐CNS cancers with PC referral (n = 80) were identified for comparison. A composite score of aggressiveness of medical care at EoL was calculated for each patient from predetermined variables. A time of eligibility for PC was defined for each patient when predetermined criteria based on symptom burden, functional status, and prognosis were met. RESULTS: Among the patients analyzed with HGG referred to PC, 59.6% (N = 31) were referred as inpatients, and 53.8% (N = 28) were referred within the last 12 weeks of life. Patients with HGG had similar aggressiveness of care at EoL regardless of PC referral, and HGG patients had less aggressive care at EoL than patients with non‐CNS cancers (p = 0.007). Care was more aggressive at EoL in HGG patients who received late versus early PC referrals (p = 0.012). Motor weakness at time of eligibility (OR = 2.55, p = 0.002) and more disease progressions (OR = 1.25, p = 0.043) were associated with less aggressive care at EoL. CONCLUSIONS: Early clinical‐ and disease‐related features predict the aggressiveness of medical care at EoL in patients with HGG. Formal PC consultation is used infrequently and suboptimally in patients with HGG. Our data suggest that the role of PC in improving EoL outcomes in HGG warrants further evaluation.
format Online
Article
Text
id pubmed-8633215
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86332152021-12-06 Aggressiveness of care at end of life in patients with high‐grade glioma Harrison, Rebecca A. Ou, Alexander Naqvi, Syed M. A. A. Naqvi, Syed M. Weathers, Shiao‐Pei S. O'Brien, Barbara J. de Groot, John F. Bruera, Eduardo Cancer Med Clinical Cancer Research BACKGROUND: Patients with high‐grade glioma (HGG) face unique challenges toward the end of life (EoL), given their aggressive trajectory and neurologic deterioration. Aggressiveness of medical care at EoL has been identified as an important quality metric for oncology patients. At this time, limited data exist around the nature of EoL care of patients with HGG. METHODS: Patients with HGG and palliative care (PC) referral seen between 2010 and 2015 were identified (N = 80). Of these, N = 52 met inclusion criteria. Random selections of patients with (1) HGG not referred to PC (n = 80), and (2) non‐CNS cancers with PC referral (n = 80) were identified for comparison. A composite score of aggressiveness of medical care at EoL was calculated for each patient from predetermined variables. A time of eligibility for PC was defined for each patient when predetermined criteria based on symptom burden, functional status, and prognosis were met. RESULTS: Among the patients analyzed with HGG referred to PC, 59.6% (N = 31) were referred as inpatients, and 53.8% (N = 28) were referred within the last 12 weeks of life. Patients with HGG had similar aggressiveness of care at EoL regardless of PC referral, and HGG patients had less aggressive care at EoL than patients with non‐CNS cancers (p = 0.007). Care was more aggressive at EoL in HGG patients who received late versus early PC referrals (p = 0.012). Motor weakness at time of eligibility (OR = 2.55, p = 0.002) and more disease progressions (OR = 1.25, p = 0.043) were associated with less aggressive care at EoL. CONCLUSIONS: Early clinical‐ and disease‐related features predict the aggressiveness of medical care at EoL in patients with HGG. Formal PC consultation is used infrequently and suboptimally in patients with HGG. Our data suggest that the role of PC in improving EoL outcomes in HGG warrants further evaluation. John Wiley and Sons Inc. 2021-11-09 /pmc/articles/PMC8633215/ /pubmed/34755486 http://dx.doi.org/10.1002/cam4.4344 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Harrison, Rebecca A.
Ou, Alexander
Naqvi, Syed M. A. A.
Naqvi, Syed M.
Weathers, Shiao‐Pei S.
O'Brien, Barbara J.
de Groot, John F.
Bruera, Eduardo
Aggressiveness of care at end of life in patients with high‐grade glioma
title Aggressiveness of care at end of life in patients with high‐grade glioma
title_full Aggressiveness of care at end of life in patients with high‐grade glioma
title_fullStr Aggressiveness of care at end of life in patients with high‐grade glioma
title_full_unstemmed Aggressiveness of care at end of life in patients with high‐grade glioma
title_short Aggressiveness of care at end of life in patients with high‐grade glioma
title_sort aggressiveness of care at end of life in patients with high‐grade glioma
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633215/
https://www.ncbi.nlm.nih.gov/pubmed/34755486
http://dx.doi.org/10.1002/cam4.4344
work_keys_str_mv AT harrisonrebeccaa aggressivenessofcareatendoflifeinpatientswithhighgradeglioma
AT oualexander aggressivenessofcareatendoflifeinpatientswithhighgradeglioma
AT naqvisyedmaa aggressivenessofcareatendoflifeinpatientswithhighgradeglioma
AT naqvisyedm aggressivenessofcareatendoflifeinpatientswithhighgradeglioma
AT weathersshiaopeis aggressivenessofcareatendoflifeinpatientswithhighgradeglioma
AT obrienbarbaraj aggressivenessofcareatendoflifeinpatientswithhighgradeglioma
AT degrootjohnf aggressivenessofcareatendoflifeinpatientswithhighgradeglioma
AT brueraeduardo aggressivenessofcareatendoflifeinpatientswithhighgradeglioma